Feed excerpt — reported by STAT News
AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but the results missed market expectations.
MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →